University of Utah study finds risk of age-related diseases may be higher in younger B-NHL survivors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

University of Utah researchers found that younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis.

These results were published in Cancer Epidemiology, Biomarkers & Prevention.

Mia Hashibe, professor in the Department of Family and Preventive Medicine at the University of Utah, director of research and practice for the Division of Public Health, and a Huntsman Cancer Institute investigator, was the study senior author. Krista Ocier, a postdoctoral researcher in the Hashibe lab, was the first author.

The authors previously established that younger NHL survivors have higher relative risk of specific heart and artery diseases than their older counterparts. In the present study, they evaluated the long-term risk of respiratory, renal, and other diseases related to aging among younger versus older NHL survivors.

The study included data from 2,129 B-NHL survivors from the Utah Cancer Registry diagnosed between 1997 and 2015. Using the Utah Population Database, the authors matched up to five

cancer-free individuals from the general population (8,969 individuals in total) with each B-NHL survivor based on sex, age, and state of birth.

They identified age-related disease outcomes through medical records from Intermountain Healthcare and the University of Utah, along with statewide health care facility data, and estimated the relative risk of these outcomes for younger and older B-NHL survivors (diagnosed at less than 65 years of age or more than 65 years of age, respectively) at least five years after cancer diagnosis.

Relative risks of acute renal failure, pneumonia, and nutritional deficiency were higher among younger than older NHL survivors compared with their respective general population cohorts. Compared with the general population, the risk of acute renal failure was increased 2.24-fold in younger survivors and 1.13-fold in older survivors; the risk of pneumonia was increased 2.42-fold in younger survivors and 1.44-fold in older survivors; and the risk of nutritional deficiencies was increased 2.08-fold in younger survivors and 1.25-fold in older survivors.

The researchers did not observe risk differences for other age-related diseases such as chronic kidney disease and osteoporosis between younger and older survivors, although NHL survivors have an overall elevated risk of these diseases.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login